Weight Loss Trade: Traders Analyze GLP-1 Market and Viking Therapeutics Surge
Viking Therapeutics shares surged up to 36% in morning trading following positive Phase 2 clinical trial results for its dual-acting obesity drug, VK2735. The study demonstrated that patients switching from … Read More